Protagonist Therapeutics
Stock Forecast, Prediction & Price Target
Protagonist Therapeutics (PTGX) stock Price Target by analysts
$61
Potential upside: 8.54%
Protagonist Therapeutics price prediction
What is Protagonist Therapeutics stock analysts` prediction?
Protagonist Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Protagonist Therapeutics in the last 3 months, the avarage price target is $61, with a high forecast of $NaN. The average price target represents a 8.54% change from the last price of $56.2.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Protagonist Therapeutics stock Price Target by analysts
Full breakdown of analysts given Protagonist Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Etzer Darout BMO Capital | 0% 0/1 | 10 months ago | $62 10.32% upside | $41.68 | StreetInsider | Previous targets (0) |
Srikripa Devarakonda Truist Financial | 0% 0/1 | 10 months ago | $60 6.76% upside | $46.46 | StreetInsider | Previous targets (0) |
Douglas Tsao H.C. Wainwright | 0% 0/2 | about 1 year ago | $50 -11.03% downside | $45.08 | StreetInsider | Previous targets (1) |
Douglas Tsao H.C. Wainwright | 0% 0/2 | over 1 year ago | $38 -32.38% downside | $32.86 | StreetInsider | Previous targets (1) |
Yasmeen Rahimi Piper Sandler | 0% 0/1 | over 3 years ago | $35 -37.72% downside | $8.61 | TheFly | Previous targets (0) |
Protagonist Therapeutics Financial Estimates
Protagonist Therapeutics Revenue Estimates
Protagonist Therapeutics EBITDA Estimates
Protagonist Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $27.35M N/A | $26.58M -2.83% | $60M 125.72% | Avg: $93.78M Low: $11.99M High: $263.98M avg. 56.3% | Avg: $145.61M Low: $108.84M High: $212.54M avg. 55.27% | Avg: $151.62M Low: $113.34M High: $221.32M avg. 4.13% | Avg: $293.24M Low: $219.20M High: $428.04M avg. 93.39% |
Net Income
% change YoY
| $-122.62M N/A | $-123.41M -0.64% | $-78.95M 36.02% | Avg: $-34.35M Low: $-194.13M High: $98.76M avg. 56.48% | Avg: $-50.55M Low: $-138.50M High: $26.67M avg. -47.13% | Avg: $-47.68M Low: $-76.17M High: $-32.02M avg. 5.67% | Avg: $55.91M Low: $37.55M High: $89.32M avg. 217.26% |
EBITDA
% change YoY
| $-125.55M N/A | $-131.37M -4.63% | $-90.34M 31.23% | Avg: $-93.78M Low: $-263.98M High: $-11.99M avg. -3.80% | Avg: $-145.61M Low: $-212.54M High: $-108.84M avg. -55.27% | Avg: $-151.62M Low: $-221.32M High: $-113.34M avg. -4.13% | Avg: $-293.24M Low: $-428.04M High: $-219.20M avg. -93.39% |
EPS
% change YoY
| -$2.65 N/A | -$2.52 4.90% | -$1.39 44.84% | Avg: -$1.37 Low: -$3.42 High: $1.74 avg. 1.35% | Avg: -$0.99 Low: -$2.44 High: $0.47 avg. 28.16% | Avg: -$0.84 Low: -$1.34 High: -$0.56 avg. 14.72% | Avg: $0.99 Low: $0.66 High: $1.57 avg. 217.26% |
Operating Expenses
% change YoY
| $153.20M N/A | $157.95M 3.10% | $153.65M -2.72% | Avg: $1.34B Low: $171.77M High: $3.77B avg. 773.70% | Avg: $2.08B Low: $1.55B High: $3.04B avg. 55.27% | Avg: $2.17B Low: $1.62B High: $3.16B avg. 4.13% | Avg: $4.19B Low: $3.13B High: $6.12B avg. 93.39% |
FAQ
What is Protagonist Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 58.07% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -194.13M, average is -34.35M and high is 98.76M.
What is Protagonist Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 52.27% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $11.99M, average is $93.78M and high is $263.98M.
What is Protagonist Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 65.37% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$3.42, average is -$1.37 and high is $1.74.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Protagonist Therapeutics stock. The most successful analyst is Etzer Darout.